MaxCyte, Inc. MaxCyte to Present Pre-Clinical CARMA Data at AACR (3008Y)
March 02 2017 - 2:01AM
UK Regulatory
TIDMMXCT
RNS Number : 3008Y
MaxCyte, Inc.
02 March 2017
MaxCyte, Inc.
("MaxCyte" or the "Company")
MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting
- In vivo research demonstrates potential of novel, proprietary,
CARMA product candidate for use in developing immunotherapies for
the treatment of solid tumours
Maryland, USA - 2 March 2017: MaxCyte (LSE: MXCT), a US-based
global company dedicated to accelerating the discovery,
development, manufacturing and commercialization of
next-generation, cell-based medicines, announced today it will
present results of pre-clinical in vivo research demonstrating the
potential of its novel, proprietary, CARMA platform for use in
developing immunotherapies for the treatment of solid tumours at
the American Association for Cancer Research (AACR) Annual Meeting
in Washington, DC on 4 April 2017.
Using MaxCyte's unique, rapid-manufacture CARMA platform in
immuno-oncology, MaxCyte and its collaborators at the Johns Hopkins
Kimmel Cancer Center demonstrated that preclinical in vivo testing
of CARMA-hMeso (i.e., mesothelin-specific mRNA CAR-transfected
peripheral blood lymphocytes) containing mesothelin-expressing
tumour cells resulted in killing of tumour cells and in increased
overall survival; with multiple repeat weekly administration of
CARMA-hMeso permitting prolonged control over tumour growth and
increased overall survival compared to a single administration.
"These data represent a major pre-clinical milestone for
MaxCyte's CARMA programme as the results demonstrate the ability of
a CARMA immunotherapy to effectively inhibit tumour growth and
prolong survival in an animal model of disease," said Doug
Doerfler, President & Chief Executive Officer. "The data
provide a strong scientific foundation for translational
development of our rapid-manufacture CARMA platform to quickly
develop tumour-targeted immunotherapies using peripheral blood
lymphocytes. We can control 'on-target, off-tumour' toxicities,
while reducing manufacturing cost and complexity for therapies
targeting both solid cancers and hematological malignancies, beyond
B-cell tumours."
Data will be shared via a poster (Permanent Abstract Number:
3748) at the AACR Annual Meeting 2017 as follows:
Session: "Innate Effectors in Immunity to Cancer"
Date: Tuesday, 4 April 2017
Time: 8:00 a.m. - 12:00 p.m. ET
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014.
About MaxCyte
MaxCyte (LSE: MXCT), is a US-based global company dedicated to
accelerating the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
platform to biopharmaceutical partners engaged in drug discovery
and development, biomanufacturing, and cell therapy, including gene
editing and immuno-oncology. With its robust delivery platform,
MaxCyte's team of scientific experts helps its partners to unlock
their product potential and solve problems. This platform allows
for the engineering of nearly all cell types, including human
primary cells, with any molecule, at any scale. It also provides
unparalleled consistency and minimal cell disturbance, thereby
facilitating rapid, large-scale, clinical and commercial grade cell
engineering in a non-viral system and with low-toxicity concerns.
The Company's cell-engineering platform is CE-marked and
FDA-accredited, providing MaxCyte's customers and partners with an
established regulatory path to commercialize cell-based
medicines.
For more information, visit http://www.maxcyte.com/
MaxCyte +1 301 944 1660
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Duncan Monteith
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
Lindsey Neville
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSSSSMEFWSEFD
(END) Dow Jones Newswires
March 02, 2017 02:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024